Lupin, Merck KGaA In Advanced Talks For Complex Generics Deal
This article was originally published in PharmAsia News
Changing landscape of the global pharmaceutical market is likely bringing India’s Lupin and German’s Merck closer. Industry sources say a deal is close to being announced.
You may also be interested in...
Merck Establishes JV With India's Sun Pharma To Develop Novel Combinations Of Branded Generics For Emerging Markets
MUMBAI - Merck & Co. is establishing a joint venture with India's Sun Pharmaceutical Industries Ltd. for a broad-based alliance to develop, manufacture and commercialize novel combinations and "incrementally innovative" branded generics in emerging markets, the two companies announced April 11
Indian Investors Turn Cautious On Compliance Concerns
A rising number of enforcement actions by major drug regulators like the U.S. FDA is slowly making investors cautious about the longer term repercussions on earnings of Indian drug makers.
Lee Takes India Compulsory License Fight To Saxagliptin
In a bold move, little known Indian drug firm Lee Pharma has applied for a compulsory license for saxagliptin in India, contending that AstraZeneca sells the diabetes drug at an exorbitant local price and that it is not being made sufficiently available. Lee also says that the originator has not responded to calls to collaborate.